Dale Webb, NASS CEO, joined the Cross Party Group for Musculoskeletal Conditions and Arthritis at the Scottish Parliament
In order to reduce ther delay to axial SpA (AS) diagnosis, we have to increase awareness. So let’s make axial SpA #ASfamousAS
Along with NRAS, Crohn’s and Colitis UK and the Psoriasis Association, NASS want to understand your experiences of switching to a biosimilar medication.
NASS has developed an APPG to ensure the NICE Spondyloarthritis Guideline is implemented
On 7 January 2019 NHS England published its long-term plan for the NHS
NASS knows that not everyone in the UK gets the same standard of care for their axial SpA (AS) – that’s why we've launched our new campaign Every Patient, Every Time.
Meet the winners of our 2018 Patients' Choice Awards. This is what excellence looks like.
Izana Bioscience, a new UK based pharmaceutical company, is running a phase 2 clinical trial for 42 patients across 10 centres in the UK for its new drug, Namilumab.
NASS Stoke on Trent need your support to help to save their hydrotherapy pool.